Evicenter
Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer
Manufacturer
Daiichi Sankyo, Inc.; AstraZeneca Pharmaceuticals LP
Prescribing information
Enhertu (opens in a new tab)
Questions
30
Last updated

All questions

Clinical trials: Enhertu (fam-trastuzumab deruxtecan-nxki) in HR-positive HER2-low or HER2-ultralow breast cancer

11 questions · 5 sources

Clinical trials

How was the Enhertu DESTINY-Breast06 trial designed?

Applies to Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

How was the Enhertu DESTINY-Breast04 trial designed?

Applies to Unresectable or metastatic HER2-low breast cancer in adults after prior chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy; HR-positive cohort (DESTINY-Breast04)

“The efficacy of ENHERTU was evaluated in study DESTINY-Breast04 (NCT03734029), a randomized, multicenter, open-label study that enrolled 557 adult patients with unresectable or metastatic HER2-low breast cancer. The study included 2 cohorts: 494 hormone receptor-positive (HR+) patients and 63 hormone receptor-negative (HR-) patients. HER2-low expression was defined as IHC 1+ or IHC 2+/ISH-, as determined at a central laboratory using Ventana’s PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody assay. Patients must have received chemotherapy in the metastatic setting or have developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. Patients who were HR+ must have received at least one endocrine therapy or be ineligible for endocrine therapy. Patients were randomized 2:1 to receive either ENHERTU 5.4 mg/kg (N=373) by intravenous infusion every 3 weeks or physician’s choice of chemotherapy (N=184, eribulin, capecitabine, gemcitabine, nab paclitaxel, or paclitaxel). Randomization was stratified by HER2 IHC status of tumor samples (IHC 1+ or IHC 2+/ISH-), number of prior lines of chemotherapy in the metastatic setting (1 or 2), and HR status/prior CDK4/6i treatment (HR+ with prior CDK4/6 inhibitor treatment, HR+ without prior CDK4/6 inhibitor treatment, or HR-). Treatment was administered until disease progression, death, withdrawal of consent, or unacceptable toxicity. The study excluded patients with a history of ILD/pneumonitis requiring treatment with steroids or ILD/pneumonitis at screening and clinically significant cardiac disease. Patients were also excluded for untreated or symptomatic brain metastases or ECOG performance status >1.” (opens the source at this quote in a new tab)

Note: Control-arm proportions are as stated on the Enhertu DESTINY-Breast04 page, for the physician's choice chemotherapy arm.

Study results

What is Enhertu PFS vs chemotherapy in HR-positive HER2-low breast cancer (DESTINY-Breast06)?

Applies to Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

Note: Median progression-free survival (PFS) by blinded independent central review at the PFS final analysis, the primary endpoint, in the HR-positive HER2-low cohort of DESTINY-Breast06 (ENHERTU n=359, chemotherapy n=354). Patients had progressed on endocrine therapy in the metastatic setting and had not received chemotherapy for metastatic disease. The comparator was physician's choice of capecitabine, nab-paclitaxel, or paclitaxel; the control-arm proportions apply to the overall study population.

What is the response rate with Enhertu in HER2-low breast cancer (DESTINY-Breast06)?

Applies to Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

Note: Table 32 columns, in order: HER2-low cohort ENHERTU (N=359) and chemotherapy (N=354), then the overall population (HER2-low and HER2-ultralow) ENHERTU (N=436) and chemotherapy (N=430). Response rates use patients with measurable disease at baseline (N in the first row), at the PFS final analysis. Patients had progressed on endocrine therapy in the metastatic setting and had not received chemotherapy for metastatic disease. The comparator was physician's choice of capecitabine, nab-paclitaxel, or paclitaxel.

What were the Enhertu DESTINY-Breast06 results by HER2 group?

Applies to Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

Note: Table columns, in order: overall study population ENHERTU and chemotherapy, HER2-low cohort ENHERTU and chemotherapy, and exploratory HER2-ultralow cohort ENHERTU and chemotherapy. Hazard ratio footnote a (unstratified) applies to the overall population, b (stratified) to the HER2-low cohort, and c to the response rates. The comparator was physician's choice of capecitabine, nab-paclitaxel, or paclitaxel. Patients had HR-positive disease that had progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease. PFS and ORR were assessed by blinded independent central review at the PFS final analysis.

How effective is Enhertu in HER2-ultralow breast cancer (DESTINY-Breast06)?

Applies to Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

Note: Exploratory subgroup of DESTINY-Breast06 (HR-positive, HER2-ultralow; ENHERTU n=77, chemotherapy n=76) at the PFS final analysis; patients had progressed on endocrine therapy in the metastatic setting without prior chemotherapy for metastatic disease. The comparator was physician's choice of capecitabine, nab-paclitaxel, or paclitaxel.

Does Enhertu help patients live longer in DESTINY-Breast06?

Applies to Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

Note: DESTINY-Breast06: HR-positive HER2-low or HER2-ultralow metastatic breast cancer that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease; ENHERTU (N=436) vs physician's choice of capecitabine, nab-paclitaxel, or paclitaxel (N=430).

How quickly does Enhertu work in HER2-low breast cancer (DESTINY-Breast06)?

Applies to Unresectable or metastatic HR-positive HER2-low or HER2-ultralow breast cancer in adults that progressed on endocrine therapy in the metastatic setting, without prior chemotherapy for metastatic disease (DESTINY-Breast06)

Note: HR-positive HER2-low cohort of DESTINY-Breast06 (after endocrine therapy, without prior chemotherapy for metastatic disease), patients with measurable disease at baseline, per Daiichi Sankyo data on file as cited on the source page; the comparator was physician's choice of capecitabine, nab-paclitaxel, or paclitaxel. DCR is disease control rate (complete response, partial response, or stable disease).

Does Enhertu improve survival vs chemotherapy in HR-positive HER2-low breast cancer (DESTINY-Breast04)?

Applies to Unresectable or metastatic HER2-low breast cancer in adults after prior chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy; HR-positive cohort (DESTINY-Breast04)

Note: Table 33 columns, in order: HR-positive cohort ENHERTU (N=331) and chemotherapy (N=163), then the overall population (HR-positive and HR-negative cohorts) ENHERTU (N=373) and chemotherapy (N=184). The HR-positive cohort columns apply to the indication covered here. Results are those of Prescribing Information Table 33. The comparator was physician's choice of eribulin, capecitabine, gemcitabine, nab-paclitaxel, or paclitaxel, in patients previously treated with chemotherapy for metastatic disease (or recurrence within 6 months of adjuvant chemotherapy). The first hazard ratio and p-value (0.64; 0.0028) are for the HR-positive cohort; the second (0.64; 0.001) are for the overall population.

How long is Enhertu PFS vs chemotherapy in HR-positive HER2-low breast cancer (DESTINY-Breast04)?

Applies to Unresectable or metastatic HER2-low breast cancer in adults after prior chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy; HR-positive cohort (DESTINY-Breast04)

Note: Table 33 columns, in order: HR-positive cohort ENHERTU (N=331) and chemotherapy (N=163), then the overall population (HR-positive and HR-negative cohorts) ENHERTU (N=373) and chemotherapy (N=184). The HR-positive cohort columns apply to the indication covered here. Results are those of Prescribing Information Table 33. The comparator was physician's choice of eribulin, capecitabine, gemcitabine, nab-paclitaxel, or paclitaxel, in patients previously treated with chemotherapy for metastatic disease (or recurrence within 6 months of adjuvant chemotherapy). PFS was assessed by blinded independent central review; PFS in the HR-positive cohort was the primary endpoint. The first hazard ratio (0.51) is for the HR-positive cohort; the second (0.50) is for the overall population.

What is the response rate with Enhertu in HR-positive HER2-low breast cancer (DESTINY-Breast04)?

Applies to Unresectable or metastatic HER2-low breast cancer in adults after prior chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy; HR-positive cohort (DESTINY-Breast04)

Note: Table 33 columns, in order: HR-positive cohort ENHERTU (N=331) and chemotherapy (N=163), then the overall population (HR-positive and HR-negative cohorts) ENHERTU (N=373) and chemotherapy (N=184). The HR-positive cohort columns apply to the indication covered here. Results are those of Prescribing Information Table 33. The comparator was physician's choice of eribulin, capecitabine, gemcitabine, nab-paclitaxel, or paclitaxel, in patients previously treated with chemotherapy for metastatic disease (or recurrence within 6 months of adjuvant chemotherapy). Confirmed objective response and duration of response were assessed by blinded independent central review; in each row the first value is the HR-positive cohort on ENHERTU and the second the HR-positive cohort on chemotherapy.